Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer

[1]  L. Esserman,et al.  Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer , 2018, npj Breast Cancer.

[2]  L. V. van't Veer,et al.  Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance) , 2018, Clinical Cancer Research.

[3]  Natali Gulbahce,et al.  Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer. , 2017, Cancer research.

[4]  L. Dizdar,et al.  Disseminated tumour cells with highly aberrant genomes are linked to poor prognosis in operable oesophageal adenocarcinoma , 2017, British Journal of Cancer.

[5]  O. Delattre,et al.  MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis , 2017, Cell Death & Disease.

[6]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[7]  E. White,et al.  Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone * , 2016, The Journal of Biological Chemistry.

[8]  Yue-zhong Wu,et al.  TACC3 promotes colorectal cancer tumourigenesis and correlates with poor prognosis , 2016, Oncotarget.

[9]  Kan Jiang,et al.  Overexpression of SPARC correlates with poor prognosis in patients with cervical carcinoma and regulates cancer cell epithelial-mesenchymal transition , 2016, Oncology letters.

[10]  U. Jeschke,et al.  Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients , 2016, Oncology.

[11]  F. Taran,et al.  Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score , 2016, Breast Cancer Research and Treatment.

[12]  R. Kimmig,et al.  Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy , 2016, Breast Cancer Research.

[13]  K. White,et al.  Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing , 2016, Genome Biology.

[14]  Kaori Tanaka,et al.  Aldehyde dehydrogenase 1A1 in stem cells and cancer , 2016, Oncotarget.

[15]  I. Holen,et al.  CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment , 2016, Journal of the National Cancer Institute.

[16]  David L. Masica,et al.  Assessing the Pathogenicity of Insertion and Deletion Variants with the Variant Effect Scoring Tool (VEST‐Indel) , 2015, Human mutation.

[17]  Peng,et al.  CAPG and GIPC 1 : Breast Cancer Biomarkers for Bone Metastasis Development and Treatment , 2016 .

[18]  P. Nelson,et al.  High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. , 2016, The Journal of molecular diagnostics : JMD.

[19]  A. Schneeweiss,et al.  Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment , 2016, Annals of Surgical Oncology.

[20]  John W. Park,et al.  Approaches to isolation and molecular characterization of disseminated tumor cells , 2015, Oncotarget.

[21]  A. Lindahl,et al.  Intracellular flow cytometry may be combined with good quality and high sensitivity RT‐qPCR analysis , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[22]  U. Rothbauer,et al.  Real-time analysis of epithelial-mesenchymal transition using fluorescent single-domain antibodies , 2015, Scientific Reports.

[23]  Yuehua Huang,et al.  TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma , 2015, Oncotarget.

[24]  C. Klein,et al.  Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes. , 2014, Cancer research.

[25]  L. Armengol,et al.  Oligonucleotide Arrays vs. Metaphase-Comparative Genomic Hybridisation and BAC Arrays for Single-Cell Analysis: First Applications to Preimplantation Genetic Diagnosis for Robertsonian Translocation Carriers , 2014, PloS one.

[26]  K. Pantel,et al.  Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients. , 2014, BoneKEy reports.

[27]  V. Georgoulias,et al.  PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer , 2014, Clinical Cancer Research.

[28]  P. Nelson,et al.  Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways , 2014, Oncotarget.

[29]  P. Bragado,et al.  Mechanisms of disseminated cancer cell dormancy: an awakening field , 2014, Nature Reviews Cancer.

[30]  M. Davidson,et al.  The cancer glycocalyx mechanically primes integrin-mediated growth and survival , 2014, Nature.

[31]  John W. Park,et al.  Advances in genomic characterization of circulating tumor cells , 2014, Cancer and Metastasis Reviews.

[32]  W. Catalona,et al.  Circulating giant macrophages as a potential biomarker of solid tumors , 2014, Proceedings of the National Academy of Sciences.

[33]  M. Hoffmann,et al.  Reliable Single Cell Array CGH for Clinical Samples , 2014, PloS one.

[34]  R. Brekken,et al.  Role of SPARC in Bone Remodeling and Cancer‐Related Bone Metastasis , 2014, Journal of cellular biochemistry.

[35]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[36]  Laurens van der Maaten,et al.  Accelerating t-SNE using tree-based algorithms , 2014, J. Mach. Learn. Res..

[37]  S. Jeffrey,et al.  Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow , 2014, BMC Cancer.

[38]  B. Ramaswamy,et al.  Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients , 2014, Breast Cancer Research.

[39]  Jason A. Grundstad,et al.  Next-Generation Sequencing of Disseminated Tumor Cells , 2013, Front. Oncol..

[40]  Peter Ulz,et al.  Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. , 2013, Cancer research.

[41]  Tom R. Gaunt,et al.  Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov Models , 2012, Human mutation.

[42]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[43]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[44]  K. Pantel,et al.  Plasticity of disseminating cancer cells in patients with epithelial malignancies , 2012, Cancer and Metastasis Reviews.

[45]  J. Bergh,et al.  Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Watson,et al.  Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease , 2012, Breast Cancer Research and Treatment.

[47]  André F. Vieira,et al.  Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype , 2011, Journal of Clinical Pathology.

[48]  John W. Park.  Disseminated tumor cells: the method is the message , 2011, Breast Cancer Research and Treatment.

[49]  G. Giles,et al.  BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received , 2010, British Journal of Cancer.

[50]  T. Fehm,et al.  HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. , 2009, Anticancer research.

[51]  Jie Zhou,et al.  Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions. , 2009, The American journal of pathology.

[52]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[53]  T. Fehm,et al.  ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients , 2008, Breast Cancer Research.

[54]  B. Trask,et al.  Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. , 2008, Cancer research.

[55]  A. Ullrich,et al.  Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. , 2008, Cancer cell.

[56]  R. Reinhardt,et al.  High-resolution array comparative genomic hybridization of single micrometastatic tumor cells , 2008, Nucleic acids research.

[57]  L. Ylagan,et al.  Isolation and Molecular Profiling of Bone Marrow Micrometastases Identifies TWIST1 as a Marker of Early Tumor Relapse in Breast Cancer Patients , 2007, Clinical Cancer Research.

[58]  J. Thiery,et al.  HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? , 2007, British Journal of Cancer.

[59]  T. Fehm,et al.  A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation , 2006, Cancer.

[60]  Gavin D. Grant,et al.  Common markers of proliferation , 2006, Nature Reviews Cancer.

[61]  F. Monzon.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[62]  R. Eils,et al.  Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. , 2005, Cancer cell.

[63]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[64]  S. Lehman-Wilzig,et al.  The method is the message , 2005 .

[65]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[66]  M. Büchler,et al.  Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. , 2004, European journal of cancer.

[67]  R. Gangnus,et al.  Genomic Profiling of Viable and Proliferative Micrometastatic Cells from Early-Stage Breast Cancer Patients , 2004, Clinical Cancer Research.

[68]  R. Eils,et al.  From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[69]  D. Pinkel,et al.  High‐resolution genomic profiling of occult micrometastatic tumor cells , 2003, Genes, chromosomes & cancer.

[70]  F. Schildberg,et al.  Estrogen receptor expression profile of disseminated epithelial tumor cells in bone marrow of breast cancer patients. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[71]  N. Stoecklein,et al.  Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer , 2002, The Lancet.

[72]  Rudolf M. Huber,et al.  Combined transcriptome and genome analysis of single micrometastatic cells , 2002, Nature Biotechnology.

[73]  G. Schlimok,et al.  Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. , 2001, The Journal of urology.

[74]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[75]  M. Speicher,et al.  Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[76]  G Kvalheim,et al.  Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. , 1999, Cytotherapy.